Diastematomyelia: Increasing Demand for The Better Treatment Options for Neurological Diseases Projected to Flourish The Market Growth at a CAGR of 3.20% During The Forecasted Period 2022- 2030

Pune, India, 2022 /MRFR Press Release/- Market Research Future published a half-cooked research report on global diastematomyelia market 

Diastematomyelia Market Highlights

Diastematomyelia is a rare anomaly resulting in the vertical splitting of the spinal cord. Females are more susceptible to this disease than males. According to the World Health Organization (2015), 1 in 2000 people suffers from this disease. However, during the last few years, the prevalence rate is increasing continuously. Increasing number of patients suffering from the disease, rising geriatric population and rising government support for research & development have driven the growth of the market. Moreover, rising demand for the better treatment, and changing lifestyle habits have fuelled the growth of the market. 

The Diastematomyelia Market is expected to reach USD 509.49 Million by 2030 at 3.20% CAGR during the forecast period 2022-2030

However, the cost of the surgery is too high and is not affordable to the people in developing region. Thus, the high cost of treatment may restrain the market.

Regional Analysis

The Americas commands the major share of the market owing to the large patient population, huge geriatric population, strong government support for research & development, and high healthcare spending. According to the report published by Brain and Spinal Cord Injury Rehabilitation, in 2015, over 259,000 people in the U.S. were suffering from spinal cord injury. Additionally, high per capita income and well developed technology have fuelled the growth of the market. 

Europe holds the second position in the global diastematomyelia market, which is followed by Asia Pacific. Huge government support will drive the growth of the market. Asia Pacific is the fastest growing diastematomyelia market. India and China hold the major share in the Asia Pacific market owing the presence of huge patient pool, rapidly developing economy and presence of huge opportunity for the development of the market.

The Middle East and Africa contributes less to the market of global diastematomyelia market. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East and African market. Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition. However, due to presence of opportunities for the development of the market African region shows the fast growth for the market.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Diastematomyelia Market Research Report

Segmentation

• The global diastematomyelia market is segmented on the basis of types, host, therapy, and end users.


• On the basis of types, the market is segmented into dual dural sac (type 1), and single sac (type 2).


• On the basis of host, the market is segmented into children and adults.


• On the basis of therapy, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into imaging techniques, and prenatal ultrasound. Imaging techniques are further categorised into Plain X-ray, CT, MRI and others. The therapy segment is further segmented into surgical intervention, scoliosis surgery, decompression (surgery), and others.


• On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers, and others. 

Key Players

The major key players in the global diastematomyelia market: 3M (U.S.), GlaxoSmithKline PLC (UK), Pfizer Inc. (U.S.), Lineage Medical, Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Bristol-Myers Squibb and Company (U.S.), B. Braun (Germany), Stryker Corporation (U.S.), Argon Medical Devices, Inc (Netherland), and Cook Medical (U.S.).